-$0.21 Earnings Per Share Expected for Viking Therapeutics, Inc. (NASDAQ:VKTX) This Quarter

Brokerages expect Viking Therapeutics, Inc. (NASDAQ:VKTXGet Rating) to announce earnings per share of ($0.21) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Viking Therapeutics’ earnings. The highest EPS estimate is ($0.18) and the lowest is ($0.24). Viking Therapeutics reported earnings of ($0.20) per share in the same quarter last year, which would suggest a negative year over year growth rate of 5%. The firm is scheduled to report its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Viking Therapeutics will report full year earnings of ($0.90) per share for the current year, with EPS estimates ranging from ($1.03) to ($0.78). For the next financial year, analysts anticipate that the business will post earnings of ($1.07) per share, with EPS estimates ranging from ($1.45) to ($0.70). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that cover Viking Therapeutics.

Viking Therapeutics (NASDAQ:VKTXGet Rating) last posted its quarterly earnings data on Wednesday, April 27th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). During the same quarter last year, the company posted ($0.19) EPS.

VKTX has been the subject of a number of recent analyst reports. StockNews.com initiated coverage on shares of Viking Therapeutics in a research note on Thursday, March 31st. They set a “sell” rating for the company. Raymond James lowered their target price on shares of Viking Therapeutics from $13.00 to $10.00 and set an “outperform” rating for the company in a research note on Thursday, February 10th. Finally, Roth Capital lowered their target price on shares of Viking Therapeutics from $20.00 to $15.00 in a research note on Thursday, April 28th. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Viking Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $14.31.

Shares of VKTX opened at $2.27 on Friday. The firm has a market capitalization of $175.64 million, a P/E ratio of -3.07 and a beta of 1.73. Viking Therapeutics has a 12-month low of $2.15 and a 12-month high of $7.20. The firm has a fifty day moving average price of $2.76 and a 200-day moving average price of $3.93.

Large investors have recently added to or reduced their stakes in the stock. Lindbrook Capital LLC lifted its stake in Viking Therapeutics by 1,062.8% in the fourth quarter. Lindbrook Capital LLC now owns 7,500 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 6,855 shares during the period. Engineers Gate Manager LP purchased a new stake in shares of Viking Therapeutics during the first quarter valued at about $37,000. Point72 Hong Kong Ltd purchased a new stake in shares of Viking Therapeutics during the fourth quarter valued at about $38,000. Qube Research & Technologies Ltd purchased a new stake in shares of Viking Therapeutics during the fourth quarter valued at about $51,000. Finally, Fox Run Management L.L.C. purchased a new stake in shares of Viking Therapeutics during the fourth quarter valued at about $52,000. 46.74% of the stock is owned by institutional investors.

Viking Therapeutics Company Profile (Get Rating)

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

Featured Articles

Get a free copy of the Zacks research report on Viking Therapeutics (VKTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.